KEGG   DRUG: Caplacizumab
Entry
D11160                      Drug                                   
Name
Caplacizumab (USAN/INN);
Caplacizumab (genetical recombination) (JAN);
Caplacizumab-yhdp;
Cablivi (TN)
Product
CABLIVI (Genzyme Corporation)
Formula
C1213H1891N357O380S10
Exact mass
27858.6828
Mol weight
27875.8075
Sequence
EVQLVESGGG LVQPGGSLRL SCAASGRTFS YNPMGWFRQA PGKGRELVAA ISRTGGSTYY
PDSVEGRFTI SRDNAKRMVY LQMNSLRAED TAVYYCAAAG VRAEDGRVRT LPSEYTFWGQ
GTQVTVSSAA AEVQLVESGG GLVQPGGSLR LSCAASGRTF SYNPMGWFRQ APGKGRELVA
AISRTGGSTY YPDSVEGRFT ISRDNAKRMV YLQMNSLRAE DTAVYYCAAA GVRAEDGRVR
TLPSEYTFWG QGTQVTVSS
(Disulfide bridge: 22-96, 153-227)
  Type
Peptide
Class
Blood modifier agent
 DG01950  Antithrombotic agent
  DG01712  Antiplatelet agent
Remark
Therapeutic category: 3399
ATC code: B01AX07
Product: D11160<JP/US>
Efficacy
Platelet aggregation inhibitor, Anti-vWF antibody
  Disease
Acquired thrombotic thrombocytopenic purpura [DS:H00225]
  Type
Monoclonal antibody
Comment
Treatment of thrombotic thrombocytopenic purpura, thrombosis
Target
VWF [HSA:7450] [KO:K03900]
  Pathway
hsa04610  Complement and coagulation cascades
hsa04611  Platelet activation
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 B BLOOD AND BLOOD FORMING ORGANS
  B01 ANTITHROMBOTIC AGENTS
   B01A ANTITHROMBOTIC AGENTS
    B01AX Other antithrombotic agents
     B01AX07 Caplacizumab
      D11160  Caplacizumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Blood Products and Modifiers
  Platelet Modifying Agents
   Platelet Modifying Agents, Other
    Caplacizumab
     D11160  Caplacizumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 3  Agents affecting metabolism
  33  Blood and body fluid agents
   339  Miscellaneous
    3399  Others
     D11160  Caplacizumab (USAN/INN); Caplacizumab (genetical recombination) (JAN)
Drug groups [BR:br08330]
 Blood modifier agent
  DG01950  Antithrombotic agent
   DG01712  Antiplatelet agent
    D11160  Caplacizumab
Target-based classification of drugs [BR:br08310]
 Not elsewhere classified
  Organismal systems
   Complement and coagulation
    VWF
     D11160  Caplacizumab (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11160
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D11160
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D11160
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11160
Other DBs
CAS: 915810-67-2
PubChem: 376219084
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system